Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment ...

Furosemide is the most widely prescribed loop diuretic in the setting of systolic heart failure (HF), yet torsemide has been shown to have less inter- and intra-individual variation in ...

Objectives In severe heart disease, parenteral administration of loop diuretic is often needed. We present clinical outcomes from episodes of care using subcutaneous continuous subcutaneous infusion ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure. Last year, the drug developer noted that FDA feedback from a 2023 Type D ...

A second session of CRRT and blood transfusion were declined by the owner. On the second day, intravenous fluids were tapered and discontinued at 30 h post-presentation. Furosemide 2 mg/kg IV and ...

However, with the exception of opioids such as morphine and hydromorphone, few drugs have randomised controlled data comparing SC and intravenous routes of administration ... 2 Over the past decade, ...

Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial ...

A short-acting diuretic such as furosemide produces significant natriuresis ... chronic CHF and chronic renin hypersecretion, intravenous loop diuretics may cause an acute increase in plasma ...